Articles

Chicago, IL—Adding docetaxel (Taxotere) to standard hormone therapy extends overall survival (OS) by a median of 10 months versus hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naïve prostate cancer, according to the results of the STAMPEDE trial. The survival benefits were more pronounced in metastatic disease and were less certain in nonmetastatic disease. Another finding of this analysis of STAMPEDE is that zoledronic acid (Zometa) had no benefit in this setting.

Chicago, IL—Immunotherapy with nivolumab (Opdivo) resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer. The 12-month OS rate exceeded 60% in patients in whom sorafenib (Nexavar) had failed, and responses occurred in patients with the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, reported Anthony B. El-Khoueiry, MD, Assistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, at the 2015 American Society of Clinical Oncology (ASCO) meeting.

Chicago, IL—The prevention of common skin cancers and precancers is possible by taking an inexpensive, widely available, oral pill twice daily. The pill—the vitamin B3 supplement called nicotinamide—cut the rate of new squamous-cell and basal-cell skin cancers by 23% compared with placebo after 1 year among patients at high risk for skin cancer. Nicotinamide also reduced the risk for developing actinic keratosis, a common precancer of the skin.

Chicago, IL—Pembrolizumab (Keytruda) achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.

Chicago, IL—In patients with metastatic colorectal cancer (mCRC) with liver-dominant metastases who received first-line FOLFOX (leucovorin, fluorouracil [Adrucil], and oxaliplatin [Eloxatin]) with or without bevacizumab (Avastin) plus selective internal radiation therapy (SIRT) compared with FOLFOX with or without bevacizumab, progression-free survival (PFS) in the liver was extended by 7.9 months, according to the results of the SIRFLOX trial, which were presented at the 2015 American Society of Clinical Oncology (ASCO) meeting.

Washington, DC—Personalized medicine will become even more critical ­­as care transitions to patient-centric, outcomes-based care models. The use of real-time data, along with an increasingly advanced understanding of cancer biology, will exponentially increase the number of treatment options for patients, making personalized treatment more effective and ultimately leading to better clinical and financial outcomes.

Washington, DC—The establishment of pathways in oncology can reduce care variation and enhance value in patient care, said Michael Kolodziej, MD, ­National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.

Washington, DC—Genomically driven medicine has created an opportunity for value in oncology by substantially improving outcomes and quality of life for patients with advanced cancer, said Vincent A. Miller, MD, Chief Medical Officer, Foundation Medicine, Cambridge, MA, at the Fifth Annual Conference of the Association for Value­Based Cancer Care.